tetano
Editor, Senior Moderator
J Infect Chemother
. 2024 Dec 6:S1341-321X(24)00325-8.
doi: 10.1016/j.jiac.2024.12.007. Online ahead of print. Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan
Manami Yoshida[SUP] 1 [/SUP], Nao Taguchi[SUP] 2 [/SUP], Yi Piao[SUP] 2 [/SUP], Rikisha Gupta[SUP] 3 [/SUP], Jami Peters[SUP] 3 [/SUP], Mazin Abdelghany[SUP] 3 [/SUP], Mel Chiang[SUP] 3 [/SUP], Chen-Yu Wang[SUP] 3 [/SUP], Mark Berry[SUP] 3 [/SUP], Hiroshi Yotsuyanagi[SUP] 4 [/SUP]
Affiliations
Introduction: Remdesivir (RDV) was approved in Japan for the treatment of coronavirus disease 2019 (COVID-19) in May 2020. However, large-scale research describing the characterized use of RDV in the inpatient setting in Japan is limited. This study aimed to describe the treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 treated with RDV.
Methods: We used a secondary nationwide administrative claims database of acute care hospitals in Japan. The study period was from October 19, 2020, to September 30, 2022. Patients with COVID-19 treated with RDV during hospitalization were included, and the proportion of patients with death and disease progression were calculated.
Results: The analysis included a total of 2,171 immunocompromised patients treated with RDV. The mean (standard deviation) age at index date was 75.1 (13.6) years. The median time to RDV initiation from hospitalization was 1.0 days (Q1-Q3: 1.0-2.0), and the median duration of RDV treatment was 5.0 days (Q1-Q3: 3.0-5.0). At RDV initiation, 53.02% (n=1,151) of patients required non-invasive positive pressure ventilation, nasal high-flow or low-flow oxygen, and 2.26% (n=49) required mechanical ventilation, extracorporeal membrane oxygenation, or intensive care unit admission. Inpatient mortality rate by day 28 was 8.98% (95% confidence interval, 7.81-10.26). By day 28, the rate of disease progression was 9.86% (n=214), and 76.83% (n=1,668) were discharged.
Conclusion: This study presents practical information on outcomes and treatment patterns of RDV in immunocompromised inpatients diagnosed with COVID-19.
Keywords: COVID-19; immunocompromised; mortality; recovery rate; remdesivir; treatment pattern.
. 2024 Dec 6:S1341-321X(24)00325-8.
doi: 10.1016/j.jiac.2024.12.007. Online ahead of print. Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan
Manami Yoshida[SUP] 1 [/SUP], Nao Taguchi[SUP] 2 [/SUP], Yi Piao[SUP] 2 [/SUP], Rikisha Gupta[SUP] 3 [/SUP], Jami Peters[SUP] 3 [/SUP], Mazin Abdelghany[SUP] 3 [/SUP], Mel Chiang[SUP] 3 [/SUP], Chen-Yu Wang[SUP] 3 [/SUP], Mark Berry[SUP] 3 [/SUP], Hiroshi Yotsuyanagi[SUP] 4 [/SUP]
Affiliations
- PMID: 39647701
- DOI: 10.1016/j.jiac.2024.12.007
Introduction: Remdesivir (RDV) was approved in Japan for the treatment of coronavirus disease 2019 (COVID-19) in May 2020. However, large-scale research describing the characterized use of RDV in the inpatient setting in Japan is limited. This study aimed to describe the treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 treated with RDV.
Methods: We used a secondary nationwide administrative claims database of acute care hospitals in Japan. The study period was from October 19, 2020, to September 30, 2022. Patients with COVID-19 treated with RDV during hospitalization were included, and the proportion of patients with death and disease progression were calculated.
Results: The analysis included a total of 2,171 immunocompromised patients treated with RDV. The mean (standard deviation) age at index date was 75.1 (13.6) years. The median time to RDV initiation from hospitalization was 1.0 days (Q1-Q3: 1.0-2.0), and the median duration of RDV treatment was 5.0 days (Q1-Q3: 3.0-5.0). At RDV initiation, 53.02% (n=1,151) of patients required non-invasive positive pressure ventilation, nasal high-flow or low-flow oxygen, and 2.26% (n=49) required mechanical ventilation, extracorporeal membrane oxygenation, or intensive care unit admission. Inpatient mortality rate by day 28 was 8.98% (95% confidence interval, 7.81-10.26). By day 28, the rate of disease progression was 9.86% (n=214), and 76.83% (n=1,668) were discharged.
Conclusion: This study presents practical information on outcomes and treatment patterns of RDV in immunocompromised inpatients diagnosed with COVID-19.
Keywords: COVID-19; immunocompromised; mortality; recovery rate; remdesivir; treatment pattern.